Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell unloaded 70,000 shares of the stock on the open market in a transaction dated Friday, August 15th. The shares were sold at an average price of $167.99, for a total value of $11,759,300.00. Following the completion of the sale, the chief executive officer now directly owns 1,027,186 shares of the company’s stock, valued at approximately $172,556,976. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.83% during mid-day trading on Wednesday, hitting $168.35. 480,187 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52-week low of $100.89 and a 52-week high of $185.43. The stock’s 50-day moving average is $162.9 and its 200-day moving average is $162.. The company has a market cap of $33.302 billion and a price-to-earnings ratio of 85.09.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 38.5% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.

ALXN has been the subject of a number of recent research reports. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $183.00.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.